• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Can Different Dosing Regimens Increase Effectiveness of the Flu Vaccine for Women Living with HIV?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • There is limited information regarding whether standard-dose, seasonal, trivalent, inactivated influenza vaccination is efficacious for women with HIV
  • Nunes et al. (The Lancet, 2020) examined the immunogenicity and safety of using different dosing schedules of inactivated influenza vaccine in pregnant women with HIV

METHODS:

  • Double-blind, randomized, controlled trial (RCT)
  • Participants
    • Pregnant women with HIV | 18 to 38 years of age
    • Gestational age 12 to 36 weeks
  • Intervention
    • Women randomized (1:1:1) in to 3 groups to receive inactivated influenza vaccine with different regimens
      • Single dose
      • Double dose
      • Two single doses 1 month apart
  • Study design
    • Participants and study personnel were masked to group allocation
    • Hemagglutination-inhibition antibody responses were measured
      • For all groups in the mothers at enrollment
      • At 1 month after each vaccine dose
      • In the single-dose and double-dose groups within 7 days of birth in the neonates
    • Safety outcomes were assessed mothers and infants until 24 weeks postpartum and analyzed in all participants who received at least one dose of vaccine
  • Primary outcomes
    • Immunogenicity
      • Seroconversion rate to each of the vaccine strains in the mothers 1 month after completion of the dosing schedule
    • Safety
      • Frequency of local and systemic reactions

RESULTS:

  • 800 pregnant women with HIV were enrolled
    • 266 were in the single-dose group | 265 in the double-dose group | 269 in the two-single-doses group
  • In the population analyzed, seroconversion rates were significantly higher in the double-dose group vs single-dose group (p≤0.019)
    • Double-dose group rates ranged from 29% to 65%
    • Single-dose group rates ranged from 18% to 49%
  • There was no difference in seroconversion rates in the two-single-doses group vs the single-dose group (p≥0.20)
    • Two-single-doses group rates ranged from 23% to 52%
  • Overall, safety outcomes were similar in the three groups
    • Injection-site reactions were increased in double-dose group

CONCLUSION:

  • A double-dose of the influenza vaccine conferred higher immunogenicity compared to single-dose regimens in women with HIV
    • Immunogenicity even in the double-dose group remains lower than women without HIV
  • The authors conclude that

These findings emphasise the need for continued efforts to find an improved influenza vaccine or vaccination strategy for this population to improve protection of their infants, such as exploring the use of high-dose inactivated influenza vaccine that is currently approved for older adults in pregnant women with HIV

Learn More – Primary Sources:

Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Vaccination in Pregnancy: CDC Recommendations and ACOG Update
Does Flu Vaccine During Pregnancy Have Long Term Adverse Effects on Children?
Does Influenza Vaccination Actually Reduce or Prevent the Flu in Older Adults?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site